Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer

Abstract

Immunotherapies have yet to demonstrate significant efficacy in the treatment of hormone receptor–positive (HRþ) breast cancer. Given that endocrine therapy (ET) is the primary approach for treating HRþ breast cancer, we investigated the effects of ET on the tumor immune microenvironment (TME) in HRþ breast cancer. Spatial proteomics of primary HRþ breast cancer samples obtained at baseline and after ET from patients enrolled in a neoadjuvant clinical trial (NCT02764541) indicated that ET upregulated b2-microglobulin and influenced the TME in a manner that promotes enhanced immunogenicity. To gain a deeper understanding of the underlying mechanisms, the intrinsic effects of ET on cancer cells were explored, which revealed that ET plays a crucial role in facilitating the chromatin binding of RelA, a key component of the NF-kB complex. Consequently, heightened NF-kB signaling enhanced the response to interferon-gamma, leading to the upregulation of b2-microglobulin and other antigen presentation-related genes. Further, modulation of NF-kB signaling using a SMAC mimetic in conjunction with ET augmented T-cell migration and enhanced MHC-I-specific T-cell–mediated cytotoxicity. Remarkably, the combination of ET and SMAC mimetics, which also blocks prosurvival effects of NF-kB signaling through the degradation of inhibitors of apoptosis proteins, elicited tumor regression through cell autonomous mechanisms, providing additional support for their combined use in HRþ breast cancer. Significance: Adding SMAC mimetics to endocrine therapy enhances tumor regression in a cell autonomous manner while increasing tumor immunogenicity, indicating that this combination could be an effective treatment for HRþ patients with breast cancer.